UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

SCHEDULE 13G

(Amendment No. 2)

 

UNDER THE SECURITIES EXCHANGE ACT OF 19341

 

F-star Therapeutics, Inc.

(Name of Issuer)

 

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

 

30315R 107

(CUSIP Number)

 

March 30, 2021

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

¨ Rule 13d-1(b)

 

x Rule 13d-1(c)

 

¨ Rule 13d-1(d)

 

 

 

1 The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

CUSIP NO. 30315R 107 13G Page 2 of 10

 

1.

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

 

Ridgeback Capital Investments L.P.                     66-0677421

 

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP** (a) ¨
(b) ¨
3.

SEC USE ONLY

 

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

 

NUMBER OF

 

SHARES

 

BENEFICIALLY

 

OWNED BY

 

EACH

 

REPORTING

 

PERSON WITH

 

5.

SOLE VOTING POWER

 

-0-

6.

SHARED VOTING POWER

 

494,360

7.

SOLE DISPOSITIVE POWER

 

-0-

8.

SHARED DISPOSITIVE POWER

 

494,360

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

494,360

10.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES

 

CERTAIN SHARES**

¨
11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

5.4%

12.

TYPE OF REPORTING PERSON**

 

OO

 

** SEE INSTRUCTIONS BEFORE FILLING OUT

 

 

 

 

CUSIP NO. 30315R 107 13G Page 3 of 10

 

1.

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

 

Ridgeback Capital Investments LLC                     72-1614961

 

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP** (a) ¨
(b) ¨
3.

SEC USE ONLY

 

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

 

NUMBER OF

 

SHARES

 

BENEFICIALLY

 

OWNED BY

 

EACH

 

REPORTING

 

PERSON WITH

 

5.

SOLE VOTING POWER

 

-0-

6.

SHARED VOTING POWER

 

494,360

7.

SOLE DISPOSITIVE POWER

 

-0-

8.

SHARED DISPOSITIVE POWER

 

494,360

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

494,360

10.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES

 

CERTAIN SHARES**

¨
11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

5.4%

12.

TYPE OF REPORTING PERSON**

 

OO

 

 

** SEE INSTRUCTIONS BEFORE FILLING OUT

 

 

 

 

CUSIP NO. 30315R 107 13G Page 4 of 10

 

1.

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

 

Ridgeback Capital Management LLC                    42-1684320

 

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP** (a) ¨
(b) ¨
3.

SEC USE ONLY

 

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

 

NUMBER OF

 

SHARES

 

BENEFICIALLY

 

OWNED BY

 

EACH

 

REPORTING

 

PERSON WITH

 

5.

SOLE VOTING POWER

 

-0-

6.

SHARED VOTING POWER

 

494,360

7.

SOLE DISPOSITIVE POWER

 

-0-

8.

SHARED DISPOSITIVE POWER

 

494,360

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

494,360

10.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES

 

CERTAIN SHARES**

¨
11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

5.4%

12.

TYPE OF REPORTING PERSON**

 

OO

 

 

** SEE INSTRUCTIONS BEFORE FILLING OUT

 

 

 

 

CUSIP NO. 30315R 107 13G Page 5 of 10

 

Item 1(a).Name of Issuer.

 

F-star Therapeutics, Inc., f/k/a Spring Bank Pharmaceuticals, Inc. (the “Company”).

 

Item 1(b). Address of Issuer’s Principal Executive Offices.

 

The Company’s principal executive offices are located at Eddeva B920 Babraham Research Campus, Cambridge, CB22 3AT United Kingdom.

 

Items 2(a). Name of Person Filing.

 

This statement is filed on behalf of the following persons with respect to shares of common stock of the Company acquired by them (the “Shares”):

 

(i)            Ridgeback Capital Investments L.P., Delaware limited partnership (“RCILP”), with respect to Shares beneficially owned by it;

 

(ii)           Ridgeback Capital Investments LLC, a Delaware limited liability company (“RCI”), with respect to Shares beneficially owned by it; and

 

(iii)          Ridgeback Capital Management LLC, a Delaware limited liability company (“RCM”), with respect to Shares beneficially owned by it.

 

The foregoing persons are hereinafter referred to collectively as the “Reporting Persons.” Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.

 

Item 2(b).Address of Principal Business Office or, if None, Residence.

 

The address of the principal business office of each of the Reporting Persons is 500 South Pointe Drive, Suite 220, Miami Beach, Florida 33139.

 

Item 2(c).Citizenship.

 

RCILP is a Cayman Island exempted limited partnership. RCI is a Delaware limited liability company. RCM is a Delaware limited liability company.

 

Item 2(d).Title of Class of Securities.

 

Common stock, $0.0001 par value per share.

 

 

 

 

CUSIP NO. 30315R 107 13G Page 6 of 10

 

Item 2(e).CUSIP Number.

 

30315R 107

 

Item 3.

 

If this statement is filed pursuant to Rules 13d-1(b) or 13d- 2(b) or (c), check whether the person filing is a:

 

(a) ¨ Broker or dealer registered under Section 15 of the Act,
(b) ¨ Bank as defined in Section 3(a)(6) of the Act,
(c) ¨ Insurance Company as defined in Section 3(a)(19) of the Act,
(d) ¨ Investment Company registered under Section 8 of the Investment Company Act of 1940,
(e) ¨ Investment Adviser in accordance with Rule 13d-1 (b)(1)(ii)(E),
(f) ¨ Employee Benefit Plan or Endowment Fund in accordance with 13d-1 (b)(1)(ii)(F),
(g) ¨ Parent Holding Company or control person in accordance with Rule 13d-1 (b)(1)(ii)(G),
(h) ¨ Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act,
(i) ¨ Church Plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940,
(j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J),
(k) ¨

Group, in accordance with Rule 13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: _______________.

 

 

Item 4.Ownership.

 

The percentages used herein are calculated based upon 9,200,320 shares outstanding as of March 24, 2021 as reported in the Company’s Annual Report on Form 10-K filed with the SEC on March 30, 2021. As of the close of business on April 9 ,2021, the Reporting Persons beneficially owned shares of the Company’s common stock in the amounts and percentages listed below:

 

 

 

 

CUSIP NO. 30315R 107 13G Page 7 of 10

 

A. Ridgeback Capital Investments L.P.
(a) Amount beneficially owned:  494,360
(b) Percent of class: 5.4%
(c) (i) Sole power to vote or direct the vote: -0-
  (ii) Shared power to vote or direct the vote:  494,360
  (iii) Sole power to dispose or direct the disposition:  -0-
  (iv) Shared power to dispose or direct the disposition:  494,360
     
B. Ridgeback Capital Investments LLC
(a) Amount beneficially owned:  494,360
(b) Percent of class: 5.4%
(c) (i) Sole power to vote or direct the vote: -0-
  (ii) Shared power to vote or direct the vote:  494,360
  (iii) Sole power to dispose or direct the disposition:  -0-
  (iv) Shared power to dispose or direct the disposition:  494,360
   
C. Ridgeback Capital Management LP
(a) Amount beneficially owned:  494,360
(b) Percent of class: 5.4%
(c) (i) Sole power to vote or direct the vote: -0-
  (ii) Shared power to vote or direct the vote:  494,360
  (iii) Sole power to dispose or direct the disposition:  -0-
  (iv) Shared power to dispose or direct the disposition:  494,360

 

RCM and RCI do not own any Shares directly. RCI is the general partner of RCILP. Pursuant to an investment management agreement, RCM maintains investment and voting power with respect to the securities held or controlled by RCI. Wayne Holman, an individual, controls RCM. By reason of the provisions of Rule 13d-3 of the Securities Exchange Act of 1934, as amended, RCM and RCI may be deemed to own beneficially all of the Shares (constituting approximately 5.4% of the shares outstanding). Each of RCM and RCI disclaim beneficial ownership of any of the securities covered by this statement, except to the extent of any pecuniary interest therein.

 

 

 

 

CUSIP NO. 30315R 107 13G Page 8 of 10

 

Item 5.Ownership of Five Percent or Less of a Class.

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.      ¨
 

Item 6.Ownership of More than Five Percent on Behalf of Another Person.

 

To the knowledge of the Reporting Persons, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, a number of the Shares which represents more than five percent of the number of outstanding shares of the Shares.

 

Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

 

Not Applicable.

 

Item 8.Identification and Classification of Members of the Group.

 

Not Applicable.

 

Item 9.Notice of Dissolution of Group.

 

Not Applicable.

 

Item 10.Certifications.

 

Each of the Reporting Persons hereby makes the following certification:

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

 

 

 

CUSIP NO. 30315R 107 13G Page 9 of 10

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

DATED: April 9, 2021

 

      Ridgeback Capital Investments L.P.

 

 

  By:

 

Ridgeback Capital Investments LLC,

      Its General Partner
    By: 

 

/s/ Bud Holman

      Name:  Bud Holman
      Title:  Director

 

      Ridgeback Capital Investments LLC
    By:

 

/s/ Bud Holman

      Name: Bud Holman
      Title: Director

 

      Ridgeback Capital Management LP
    By:

 

/s/ Bud Holman

      Name: Bud Holman
      Title: Authorized Signatory

 

 

 

 

CUSIP NO. 30315R 107 13G Page 10 of 10

 

EXHIBIT INDEX

 

Exhibit Number Exhibit Description
99.1 Joint Filing Agreement*

 

 

*Previously filed.